SecBot SecBot
144 ·Filed Jun 11, 2026

TNGX

Tango Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed5mo ago SEC0001950047-26-005968
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine Form 144 filing for a tax-covering sale on vested restricted stock by an officer. The $133K amount is immaterial, no trading signal is generated by this notice of intent to sell.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$30.94
T+0 close · Jun 11, 2026 · via day close
Latest settled
−22.43%
T+60 · $24.00
Vs SPY
−25.21%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 12 $30.94entry
  2. T+1 · 5mo ago +6.33%α +4.57% · $32.90
  3. T+5 · 5mo ago −9.60%α −10.27% · $27.97
  4. T+20 · 4mo ago +0.39%α −1.39% · $31.06
  5. T+60 · 2mo ago −22.43%α −25.21% · $24.00
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Officer Daniella Beckman filed a Form 144 notice of intent to sell 4,446 shares of TNGX common stock, with an estimated value of approximately $133,380. The shares were acquired upon vesting of restricted stock between April 2017 and May 2026. This is a routine, tax-related sale that is negligible relative to Beckman's 1.79M share holdings and the company's $4.1B market cap.

Key Facts

  • Officer Daniella Beckman intends to sell 4,446 shares of TNGX common stock
  • Estimated sale value of approximately $133,380 (roughly $30/share)
  • Shares acquired upon vesting of restricted stock from April 2017 through May 2026
  • Sale represents approximately 0.25% of Beckman's disclosed 1,791,726 share holdings
  • Broker for the proposed sale is Morgan Stanley Smith Barney LLC

Financial Impact

~$133,380 sale value, representing less than 0.01% of TNGX's $4.1B market cap and a trivial reduction in insider holdings

insider holdings

Risk Factors

  • No material risks identified from this routine insider sale filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
78% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-005968
Document: 0001950047-26-005968-index.html0001950047-26-005968
Document: 0001950047-26-005968.txt0001950047-26-005968

Track record

27 reports on TNGX

Performance horizon

3 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +29.28% at T+60 after the Jun 8, 2026 report. 5 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.22 Now $24.17 +0.21% settles Feb 16
  2. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.50 Now $24.17 +1.35% settles Feb 12
  3. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $22.74 Now $24.17 +6.29% settles Feb 5
  4. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $21.50 Now $24.17 +12.42% settles Feb 4
  5. Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $20.87 Now $24.17 +15.81% settles Feb 3
  6. Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
  7. Nov 2, 202614d ago 144 Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
  8. Oct 23, 202624d ago 8-K Bullish 7/10 Entry $23.34 Now $24.17 +3.56% settles Jan 21
  9. Aug 11, 202613w ago 8-K Bearish 6/10 Entry $25.58 to $23.18 Now $24.17 +5.51% ▲ +9.38% +4.51% vs SPY
  10. Aug 11, 202613w ago 8-K Bullish 7/10 No price data
Showing 10 of 27

US Market Status

Market Closed · Opens in 9h 16m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 11, 2026